OverviewSuggest Edit

Pacific Biosciences of California (PacBio, formerly known as Nanofluidics) is a company developing a platform for genetic analysis. It supplies PacBio Sequel Systems that conduct, monitor, and analyze biochemical sequencing reactions. The company also provides consumables, including reagents, disposables, and proprietary SMRT cells. Additionally, PacBio offers analytical software tools, SMRT (single molecule, real-time sequencing) compatible products, and related services.

TypePublic
Founded2004
HQMenlo Park, CA, US
Websitepacb.com
Overall CultureC-

Latest Updates

Employees (est.) (Dec 2020)412(+2%)
Job Openings105
Revenue (FY, 2020)$78.9 M(-13%)
Share Price (Oct 2021)$24.4
Cybersecurity ratingCMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Pacific Biosciences of California

Christian Henry

Christian Henry

CEO & President, Director
Chris Seipert

Chris Seipert

Vice President and General Manager of Americas and EMEA
Susan Kim

Susan Kim

Chief Financial Officer
Michele Farmer

Michele Farmer

Chief Accounting Officer
Peter Fromen

Peter Fromen

Chief Commercial Officer
Mike Goloubef

Mike Goloubef

Vice President, Manufacturing and Quality
Show more

Pacific Biosciences of California Office Locations

Pacific Biosciences of California has an office in Menlo Park
Menlo Park, CA, US (HQ)
1305 O'Brien Dr
Show all (1)

Pacific Biosciences of California Financials and Metrics

Pacific Biosciences of California Revenue

Embed Graph
View revenue for all periods
Pacific Biosciences of California's revenue was reported to be $78.89 m in FY, 2020
USD

Revenue (FY, 2020)

78.9m

Gross profit (FY, 2020)

32.6m

Gross profit margin (FY, 2020), %

41.3%

Net income (FY, 2020)

29.4m

EBIT (FY, 2020)

(104.4m)

Market capitalization (15-Oct-2021)

5.2b

Closing stock price (15-Oct-2021)

24.4

Cash (31-Dec-2020)

81.6m

EV

5.1b
Pacific Biosciences of California's current market capitalization is $5.2 b.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

33.9m26.0m28.2m60.6m92.8m90.7m93.5m78.6m90.9m78.9m

Revenue growth, %

115%53%(2%)

Cost of goods sold

20.8m25.0m21.8m37.2m39.3m46.6m58.8m53.5m56.3m46.3m

Gross profit

13.0m940.0k6.4m23.4m53.5m44.2m34.7m25.1m34.6m32.6m
USDQ2, 2011

Financial Leverage

1.1 x
Show all financial metrics

Pacific Biosciences of California Operating Metrics

FY, 2016

Patents (Foreign)

133

Patents (US)

221

Patents Pending

187
Show all operating metrics

Pacific Biosciences of California Revenue Breakdown

Embed Graph

Pacific Biosciences of California revenue breakdown by geographic segment: 56.0% from North America, 22.1% from Europe and 21.9% from Asia

Pacific Biosciences of California Cybersecurity Score

Cybersecurity ratingPremium dataset

C

79/100

SecurityScorecard logo

Pacific Biosciences of California Online and Social Media Presence

Embed Graph

Pacific Biosciences of California Company Culture

  • Overall Culture

    C-

    65/100

  • CEO Rating

    F

    50/100

  • Compensation

    D+

    59/100

Learn more on Comparably

Pacific Biosciences of California News and Updates

Pacific Biosciences of California, Inc. to Present at Upcoming Investor Conference

MENLO PARK, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) announced today that its executives will be speaking at the following investor conference:

Pacific Biosciences of California, Inc. Second Quarter 2021 Financial Results Call

MENLO PARK, Calif., July 19, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its second quarter 2021 financial results on Tuesday, August 3, 2021, at 4:30pm Eastern Time.

Pacific Biosciences of California, Inc. to Present at Upcoming Investor Conferences

MENLO PARK, Calif., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) announced today that its executives will be speaking at the following investor conferences:

Should You Book Profits In Pacific Biosciences of California After A Massive 13x Rally?

After a large 13x rise since the March 23 levels of last year, at the current price of around $36 per share we believe Pacific Biosciences of California stock, a biotechnology company that develops gene sequencing systems, has reached its near-term potential. PACB stock has rallied from $3 to $36...

Pacific Biosciences of California, Inc. Announces Preliminary Fourth Quarter 2020 Revenue

MENLO PARK, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (the “Company”) (NASDAQ: PACB), a leading provider of high-quality sequencing platforms, today announced unaudited preliminary revenue of approximately $27 million for its fourth quarter ended December 31…

Pacific Biosciences of California, Inc. Announces Pricing of Public Offering of Common Stock

MENLO PARK, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB) (“Pacific Biosciences” or the “Company”) today announced that it has priced its previously announced underwritten public offering of 19,430,000 shares of its common stock at a price to the …
Show more

Pacific Biosciences of California Blogs

Long-read HiFi Sequencing is Helping Researchers Tackle Biggest ALS Challenges

PacBio long-read sequencing recently uncovered a tandem repeat linked to ALS. This article reviews the discovery and shares the interactive case study...

ESHG 2021: How HiFi Sequencing is Closing the Gaps in Rare Disease Research

This year at ESHG, we featured discussions and poster presentations unravelling how HiFi Sequencing is unlocking discovery in rare disease.

UW Scientists Resolve Key Segmental Duplication Region with PacBio Sequencing

Researchers have resolved the TCAF gene locus and identified more than 100 kb that had previously been missing in the human reference genome.

SMRT Grant Winners: When Accuracy Matters Scientists Choose HiFi Sequencing

Congratulations to these intrepid scientists and recipients of our HiFi for Accuracy SMRT Grant.

Young Investigators Share Stellar Science, Career Advice and Bioinformatics Tools at SMRT Leiden 2021

SMRT Leiden 2021 featured young investigators in discussion about long-read sequencing, bioinformatics, career advice, and more. View on demand now.

Data Release: Human Microbiome Samples Demonstrate Advances in HiFi-Enabled Metagenomic Sequencing

PacBio has released a new data set to help scientists see how long-read sequencing and HiFi data can aid in metagenomic research.
Show more

Pacific Biosciences of California Frequently Asked Questions

  • When was Pacific Biosciences of California founded?

    Pacific Biosciences of California was founded in 2004.

  • Who are Pacific Biosciences of California key executives?

    Pacific Biosciences of California's key executives are Christian Henry, Chris Seipert and Susan Kim.

  • How many employees does Pacific Biosciences of California have?

    Pacific Biosciences of California has 412 employees.

  • What is Pacific Biosciences of California revenue?

    Latest Pacific Biosciences of California annual revenue is $78.9 m.

  • What is Pacific Biosciences of California revenue per employee?

    Latest Pacific Biosciences of California revenue per employee is $191.5 k.

  • Who are Pacific Biosciences of California competitors?

    Competitors of Pacific Biosciences of California include Personalis, Roche and Qiagen.

  • Where is Pacific Biosciences of California headquarters?

    Pacific Biosciences of California headquarters is located at 1305 O'Brien Dr, Menlo Park.

  • Where are Pacific Biosciences of California offices?

    Pacific Biosciences of California has an office in Menlo Park.

  • How many offices does Pacific Biosciences of California have?

    Pacific Biosciences of California has 1 office.